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Patients with obstructive jaundice have an increased perioperative complication rate. Sepsis, bleeding,
wound problems, renal and liver malfunction are all seen in these patients. Assessment ofimmune function
has been an active research area in these patients. This review will examine various aspects of immune
functions in obstructive jaundice, discuss the recent research results and controversies and then go on to
discuss the relevant mediators of immune function and some possible implications for treatment.
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It is accepted that patients with obstructive jaundice
have increased perioperative complications and mor-
tality1. Collected data has shown that the mortality
can be as high as 13%, particularly in patients with:
haematocrit less than 30%, bilirubin higher than 200gm/
1, and with malignant disease2. The common complica-
tions are: bacteribilia and sepsis3-s, gastrointestinal
bleeding1’5’7’9, gastroduodenal mucosal erosions1, renal
failure1’11’15, impairedwound healing1’6’7’16, haemorrhage
and blood coagulation disorderss’8’17 including dissemi-
nated intravascular coagulation (DIC) 9,8. This group of
patients is therefore of great interest and importance in
surgical practice and research.
IMMUNE FUNCTIONS IN OBSTRUCTIVE
JAUNDICE
Reticuloendothelial System (RES)-Mononuclear
Phagocyte System
Historically, the term RES was used to describe a popu-
lation of cells in the reticular connective tissue of the
spleen, liver and lymphoid tissue. The alternative
Mononuclear Phagocyte System is sometimes used
nowadays. This population includes: monocytes, mature
macrophages, histiocytes in the tissues, alveolar
macrophage in the lung, Kupffer cells in the liver, and
macrophages in the spleen, lymph nodes, peritoneum,
and other areas.
These cells play a central role in immune regulation 19.
Apart from being phagocytic and antigen presenting,
they constitute a secretory organ producing over 100
substances2. These range from molecules as small as
32 kDa up to 440 kDa and include:-a variety of lytic
enzymes, proteins, lipid metabolites and oxygen free
radicals. In recent years the monocyte/macrophage
has been found to be a principal source ofTNFc, IL-
l, IL-6, IL-8, and macrophage inflammatory proteins
(MIPs)2’)1. It is also a major contributor of other
cytokines: GM-CSF, M-CSF, EGF, IGF-I, IL-10, IL-
l2, TGF[3 PDGF and IFN21-26.
Much of the work on jaundiced patients has con-
centrated on the RES phagocytic function. For many
years, it has been recognised that the RES phagocytic
and clearance functions are disturbed in jaundice. In
1957 Halpern
27 showed that in bile duct ligated rats
the RES phagocytic activity for carbon particles was
stimulated, later work produced contradictory re-
suits. Table I summarises the RES functions in both
animal and human studies.
Other aspects of the monocytic system have
been studied to a lesser extent. Lee
34 showed that in
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Species Assay
TABLE RES functions in jaundice
Rats Carbon infusion
Sulphur colloid
Bacteria
Staphylococcus aureus
Endotoxin
Bacteria
Candida albicans
Cell Migration
Bacteria
Endotoxin
Dogs Bacteria
Human Microspheres
Microaggreated albumin
Comment References
Phagocytosis-increased 27
Uptake-decreased 4, 28
Clearance-delayed 29
Lung macrophage 30
phagocytosis-decreased
Kupffer cell uptake-increased 31
Kupffer cell uptake-decreased 32
Kupffer cell uptake-decreased 33
RES cell-movement reduced 34
Clearance-decreased 35-39
Kupffer cell clearance decreased 40
Liver uptake no-change 41
Clearance-decreased 42
Clearance-decreased 43, 44, 45
jaundiced rats, the migration of reticulo-endothelial
cells and fibroblasts into granulomata was impaired
and thismay contribute to the delay in wound healing
observed injaundice. Hultberg in 198148 reported that
patients with jaundice have a markedly increased
blood level ofone ofthe lysosomal hydrolases, acetyl-
13 hexosaminidase (EC 3.2.1 52), an enzyme, whichis
critically deficient in Tay-Sachs and Sandoff syn-
drome49’5. An increased plasma enzyme level is seen in
sepsis51, necrotizing enterocolitis
52 and some malignan-
cies53-55. Hultberg and others48’56’69 suggested that this
may be due to decreased clearance by Kupffer cells in
these diseases. Besides enzyme clearance the mono-
cyte/macrophage is also a rich source of this enzyme,
57 secreting lysosomal enzymes spontaneously and in
response to stimuli58’59. This has lead to the study
of the relationship between monocyte/macrophage
hexosaminidase secretion and the plasma hexo-
samindase levels in these patients. It appears that
monocytes from these patients have increased pro-
duction of hexosaminidase both spontaneously and
60 after stimulation These cells also have an increased
total enzyme content, suggesting that increased pro-
duction from activated monocyte/macrophages, as
well as decreased clearance, may both contribute to
the increased blood level of hexosaminidase.
Although most studies have shown impaired RES
function in jaundice, some recent studies, have, how-
ever, shown the converse. Adachi et al.
3 in rat stud-
ies, have shown that the multiple functions ofhepatic
macrophages may be separately modified: the
phagocytic index for injected 5Cr-endotoxin is in-
creased 2 weeks after ligation of the bile duct.
Superoxide and prostaglandin E2 production by he-
paticmacrophages and peripheral monocytes are also
increased, but IL-1 release is not changed and IL-2
receptors on hepatic macrophages are reduced. This
indicates that macrophages injaundiced .animals dem-
onstrate altered function but is this "malfunction"?
Allen eta/.41, directly measured the hepatic uptake of
bacteria in a dog model and found there was no
difference in bacterial uptake between controls, partial
or complete obstructive jaundice. Semeraro
46 showed
that jaundiced patients’ monocytes have a greatly in-
creased procoagulant activity (tissue factor) and this
may contribute to activation of blood coagulation in
severe jaundice. A recent study from Hines et al.47 has
shown that after bile duct ligation, liver macrophages
show a significantly increased proliferation and activa-
tion, which last up to 4 weeks.
Assessment of RES function in intact animals is
problematic, because although themononuclearphago-
cytic system is one ofthe key factors in the clearance of
bacteria and particles from the blood stream, the
process of clearance is very complex and the RES is
only part of the process. Various opsonins" (such as
IgG, IgM, complement factors, and adhesion mol-
ecules), receptors, intracellular signalling pathways,
and the cytoskeleton are also required. An in vivo
clearance study of infused particles (bacteria and
others) is therefore not able to define the specific
defect in the clearance process6. There are similar
problems with any evaluation ofthe restoration ofthe
RES phagocytosis defect. The stimuli used in most
studies are not specific for phagocytosis, or even for
the RES itself. They almost all stimulate other func-
tions oftheRES (superoxide production for example)
and other immune functions. More specific and pre-IMMUNE FUNCTIONS IN OBSTRUCTIVE JAUNDICE 131
cise methods are needed to define the multiple aspects
ofRES function in these patients.
Neutrophils
Neutrophils, the largest population of immune cells,
play a key role in destroying infecting micro-organ-
isms in vivo. These cells are normally "at rest" but can
be stimulated to make a response, for example, anti-
bacterial function. This will involve chemotaxis,
phagocytosis, intracellular killing (by activation of
a non-mitochondrial oxidase system) and secretion
of various products. Recently, another neutrophil
functional state, known as "primed" has been re-
cognised 62,63. In this state, neutrophils are "prepared for
action" and respond to stimulation in an aggressive
hyper-reactive manner. This is not merely an additive
or synergisitic effect of activating agonists64’65 but
results from an as yet unidentified chemical change
within the neutrophils.
Chemotaxis an d Phagocytosis
Neutrophil phagocytosis of S. Aureus is reduced in
jaundiced patients, but the phagocytosis ofzymozan
is intact3’66. Reduced phagocytosismayhave some bear-
ing on the morbidity and mortality of jaundiced pa-
tients67. The chemotaxis ofneutrophils has been shown
to be impaired68, but this has not been confirmed by
others3,66.
Superoxide Production and Priming by Cytokines
In biliary obstruction increased superoxide produc-
tion by neutrophils, after stimulation with fmlp,
PMA or zymozan can last as long as 5 days83. This
hasbeen seen inbothjaundiced animals
86 and in patients 87.
it has been shown that jaundiced patients with a poor
immediate clinical outcome have higher neutrophil
superoxide production prior to death88. Neutrophils
from jaundiced patients, unlike controls, cannot be
primed by cytokines TNFo, IL-6, or IL-887. Culture
of normal neutrophils with jaundiced serum fails to
reproduce the increase of superoxide production ob-
served in jaundice. This may indicate that other ele-
ments may be required, for example monocyte/
macrophages and the cytokines they can produce83. In
these patients there is an increased blood level ofsuch
cytokines and an increased production from mono-
cytes. It has been suggested that neutrophils from
jaundiced patients are ’pre-primed’ in vivo and there-
fore produce more toxic products when subjected to
subsequent stimulation. Some of the bile salts, which
are markedly increased in jaundice may also prime
neutrophils at low concentration and stimulate
neutrophil at higher concentrations and this may ex-
aggerate the production of superoxide in jaundice89.
Schmeling
9 reported thatPMA when injected into
bile ducts results in neutrophil infiltration into the
duct tissue and subsequent duct necrosis and fibrosis.
This suggests a potential role for neutrophils in the
pathogenesis of tissue damage in jaundice. Neutrophil
adhesion, an important prelude to extravasation is also
impaired in jaundiced91.
The ability ofneutrophils to be primed is interesting.
Various cytokines (IL-1, TNFo, IL-6 etc) and interest-
ingly, LPS and some bile salts are able to prime
neutrophils at low concentrations. The increased cyto-
kine levels, endotoxaemia and bile salt levels in jaun-
diced patients maythereforebe ofparticularimportance.
Various primers can act together to give synergistic
effects on neutrophil functions92. Non-cytokine prim-
ers also include leukotriene B4, cathepsin G, elastase,
ATP, lithocholate9, LPS62’93 and inositol 6 phos-
phatase (InsP6). It is important that these various
primers can enhance the production ofreactive oxygen
metabolites, (such as H202, hypochlorite and
superoxide) and proteolytic enzymes (such as
collagenases and elastases), which all have a potential
for causing tissue damage. There is both clinical94-97’
101-03 and experimental
9s-1 evidence suggesting that:
(1) tissue damage from activated neutrophils,
including damage to endothelial cells, lung,
heart, kidney, cartilage and liver, is greatly
enhanced by "priming",
(2) the increased concentration of circulating
primers, neutrophil priming and the patients
prognosis are all closely linked.
In summary, the priming of neutrophils is a cru-
cial part in the beneficial anti-microbial activity of
these cells, but it may increase the harmful genera-
tion of tissue damaging molecules. When the sys-
temic levels of "priming" agents reach a critical
point, the damage caused by activated neutrophils
may trigger a feedback loop in which further inflam-
mation, cytokine production and tissue damage can
eventually lead to multi-organ damage. As more and
more primers are discovered, it is becoming clear
that strategies aimed at preventing the action of an
individual agent may be futile. There remains a need
to find effective, safe and economic strategies for
controlling neutrophil priming.132 W.G. JIANG AND M.C.A. PUNTIS
Lymphocytes
Although lymphocytes are one of the most important
parts ofthe immune system, the changes in this popu-
lation have been rather less well studied in jaundiced
patients.
Vierucci14 reported that patients with cholestasis
have a decreased lymphocyte rosette formation
(E rossettes) which is reversible by culture with nor-
mal human sera. There is an inhibition of cellular
immunity in jaundice and this may be due to
endotoxin37,1.
It has been shown in animal studies that obstruc-
tive jaundice inhibits the lymphocyte stimulation in-
dex using PHA, conconavalin A or pokeweed
mitogen16’17. This may be due to agents in the jaun-
diced blood as jaundiced lymphocytes when cultured
with control serum have their impaired function re-
stored. It has also been shown that patients with
jaundice, particularly those with bilirubin over 220
gm/1 have an impaired delayed hypersensitivity re-
sponse compared with controls19. These results how-
ever have failed to be repeated in other studies, in
which the T and B cell numbers, T cell responses to
mitogens,NK cell functions and serum immunoglobulin
were found to be normal8.
The in vivo and in vitro mitogenic response of
lymphocytes to PHA, allogeneic F344 antigen and
concanavalin A are depressed in jaundiced animal
modelsl-l2. Lymph node cells show similar changes.
This suppression can be seen as early as 3 days after bile
duct ligation and bears no relationship to the level of
bilirubinl3,TM.
Finally, IL-2 receptor, an indicator ofT cell activa-
tion has been found to be increased in patients with
obstructive jaundice15.
Humoral Immunity
Patients with obstructive jaundice of either benign or
malignant aetiology have increased levels ofsecretory
IgA, total IgA, and IgA-CIC that correlate with in-
creased C3 levels 116. These patients also show raised
levels of circulating IgA and IgG-containing immune
complexes that are correlated with the levles of
endotoxin and with bacteraemia7. Increased deposi-
tion of glomerular IgA is seen in a large proportion of
jaundiced patients and in animal models118’19’12. These
reports suggest a contribution ofimmune dysfunction to
renal failure. Other studies show an increase in CA19-9 2.
The B lymphocyte functions has been shown not to be
affectedl.
Cytokines
Cytokines are a group of protein molecules that are
widely produced and are key mediators in many physi-
ological and pathological processes, includingimmune
regulatory effects. For example, TNF, IL-1 and IL-6
are key mediators in the endotoxin induced cascade,
acute phase response and malignant cachexia. TGF[3 is
one of the few monocyte down-regulators; it inhibits
some monocyte secretions and also other functions. IL-
l2, initially known as natural killer cell stimulatory
factor demonstrates the important contribution made
by products of the monocyte/macrophage population
to the regulation ofcellularand natural immunity24’22’23.
Cytokine dysregulation has been reported in patients
with sepsis, trauma, burns, inflammatory bowel dis-
eases, severe acute pancreatitis, meningitis, alcoholic
hepatitis and malaria. The cytokine levels have been
reported to be related to the patients, prognosis124-131.
The blocking of their production with anti-endotoxin
antibodies or anti-monocyte-activators
132-34 or block-
ing of their actions with anti-cytokine antibodies or
cytokine antagonists7’135-36 has recently been reported
to have a beneficial role in some of these diseases
although these are at present controversial resultsTM.
Monocytes from jaundiced patients show an in-
creased production ofTNFx and IL-6, but not of IL-1
or TGF[31’137. Two independent laboratories have re-
ported the existence of soluble TNF antagonist/bind-
ing protein/inhibitor), a factor that binds to TNF and
reduces its biological effects. Two forms ofTNF solu-
ble receptor have been reported (sTNFR-P55 and
sTNFR-P75), these are natural TNF inhibitors that
can bind to TNF and abolish its effects. Bemelmans et
al.
38 reported from their animal study (mice) that after
bile duct ligation, there are increased serum levels of
both forms of soluble receptors, by ELISA assay,
compared with controls. This is co-incident with in-
creased levels ofthe biologically in-active form ofTNF
in the circulation, by ELISA. This confirmed the results
from others
139 using a bioassay, that there are increased
levels of TNF inhibitor in jaundiced humans. Jaun-
diced patients who have a poor immediate clinical
outcome have an increased level ofTNF in the circula-
tion with increased production of TNF but relatively
low levels of TNF inhibitor. The harmful effects of
increased TNF production are diminished by binding
to the inhibitor, when this balance is disturbed damage
to the host could result. In patients with jaundice139,
there is an imbalance between the level ofTNF inhibi-
tor and the production ofTNF by monocytes.
Blood levels of various cytokines have also been
studied. Bemelmans 140 showed that in jaundicedIMMUNE FUNCTIONS IN OBSTRUCTIVE JAUNDICE 133
animals, there are increased blood TNF and IL-6
levels which may suggest the production of these
cytokines by the monocyte/macrophage is increased.
In studies with jaundiced patients blood levels of IL-
6, and TGF[3 are also increased
142 and this may be
related to the increased acute phase protein produc-
tion in these patients as IL-6 is one ofthe most potent
stimuli for acute phase protein synthesis by hepato-
cytes.
Platelet activation factor (PAF), an important me-
diator in inflammation and endotoxic shock, has re-
cently been shown to be produced in large quantities by
Kupffer cells and the expression of its mRNA in-
creased in bile duct ligated rats43. This may be a result
of portal endotoxaemia. The plasma level after com-
mon bile duct ligation in the rabbit, is also rapidly
increased44. This peptide is not only a water and elec-
trolyte regulator, but also an immune cell primer. In
contrast to PAF and atrial natriueretic peptide, circu-
lating levels of insulin-like growth factor I, (IGF-I) in
jaundiced animal (rats in this instance) are decreased
compared with controls4.
From the literature it seems that, broadly speaking,
in jaundiced patients immune function is inhibited,
(almost certainly the RES, perhaps cellular and some
aspects of neutrophil immunity). There are two fac-
tors however in these studies which raise some doubts.
Firstly, there is some inconsistency in these studies and
secondly, the conclusion that immune function is de-
pressed in jaundiced patients is not in line with the
fact that in these patients there is endotoxaemia,
hyperbilirubinaemia, and other factors which are
strong stimulators ofimmune cell function (see below).
This area needs further clarification.
Apart from the systemic immune dysfunction,
jaundiced patients also have local immunity dysfunc-
tion. Sung et al.
46 recently reviewed the biliary tract
defence mechanisms against bacterial infection.
These mechansims are: tight junctions between
hepatocytes, Sphincter of Oddi, bile flow, bile salts in
the gut, Kupffer cells, and secretory immunological
responses particularly secretory IgA in the biliary and
intestinal tract. Most of these mechanisms are dam-
aged in jaundiced patients. Biliary obstruction raises
the biliary pressure which causes damage to the tight
junctions. Bile salt concentration increases in the cir-
culation which can damage host immune function.
Kupffer cell malfunction is discussed earlier as part of
the RES. In addition, ifbiliary IgA cannot be secreted
into the gut the increased level of circulating igAmay
lead to increased deposition in the kidney causing
renal damage.
MEDIATORS RESPONSIBLE FOR THE
IMMUNE FUNCTION CHANGES IN
JAUNDICE
Almost 20 years ago Vierucci
14 showed that the de-
pressed lymphocyte function in cholestatic patients could
be reversedbynormalhuman seraand cholestatichuman
sera could casue E rossettes with normal lymphocytes to
be decreased. One or more factors in the serum will be
responsible for the immune changes and although there
are now more contenders than the bilirubin and bile salts
suggested by these authors the full picture is still not yet
clear.
Endotoxin
There is increasing recognition of the existence ofboth
portal and systemic endotoxaemia in obstructive jaun-
dice. This has been confirmed both in animal studies
147,148,149 and in clinical studies9’3’15-53. Endotoxaemia
has been postulated as one of the key factors in the
pathophysiology of complications in jaundice, such as
renal damage, coagulation disorders, and Multiple Sys-
tem Organ Failure (MSOF).
Possible contributors to endotoxaemia in these pa-
tients are as follows149:
(1) Absence of bile salts in the gut allows changes in
the bacterial flora, and loss of the emulsifying
anti-endotoxin effects of bile salts, which results
in a large, pool of endotoxin in the colon.
(2) Reduced Kupffer cell up-take ofendotoxin which
allows it to enter the systemic circulation, clearly
shown by Clements et al.4.
(3) Bacterial translocation can be promoted by fac-
tors, such as biliary infections, altered mucosal
permeability and biliary obstructionTM.
Endotoxin initiates a cascade of pathophysiological
events71, involving most systems and organs. Apart
from the well recognised pathways of endotoxin acti-
vating the complement system, the coagulation sys-
tem, and a "direct" effect on blood elements72, recent
work has proved that endotoxin induces a cytokine
cascade, including TNFo, IL-1, IL-6, and IL-8, these
cytokines mediate further biological processes73-76.
Greve1 showed that endotoxin may contribute to
macrophage activation in jaundice. In germ free rats,
jaundice does not cause macrophage activation, but
in normal rats there is activation of macrophages.
Endotoxin has also been shown to stimulate 13-
glucuronidase production from macrophages and
PAF production from Kupffer cells143’156.134 W.G. JIANGAND M.C.A. PUNTIS
The role ofendotoxaemia inTNF production in liver
disorders has been further investigated by Badger
et al. 157, who showed, in a rabbit model, that
endotoxaemia in combination with impaired hepatic
clearance of endotoxin may potentiate TNF produc-
tion. This combination seems to operate in jaun-
dice31’6’137’14J42. Although most work suggests that
endotoxin stimulates monocyte/macrophage phago-
cytosis77-81, others imply the opposite effects of LPS on
different subpopulations of macrophages82. This area
certainly deserves more indepth studies in jaundice.
Bile Salts
The increase in serum bile salts in jaundiced patients
has important pathological implications, as bile salts
can have profound effects on immune parameters.
Bile acids, chenodeoxycholate, deoxycholate, and
ursodeoxycholate all have inhibitory effects on
lymphocyte mitogenesis induced by various sti-
muli158,159. Lymphocyte proliferation and IL-2 produc-
tion are also reversibly inhibited by these bile acids,
but the cell surface receptor numbers are not
affected167. Bile acids increase [3-glucuronidase pro-
duction in vitro16. This may partly explain the in-
creased level in the blood and production from
monocytes in patients with jaundice48’6’6.
Bilirubin
The in vitro and in vivo effects of a raised bilirubin are
unfortunately rather controversial and less conclusive.
Inhibitory Effects
In vitro bilirubin can neutralise migration inhibition
in a tuberculin hypersensitivity study6. Neutrophil
hexose-monophosphate shunt activity is an impor-
tant prerequisite for microbiocidal function and
bilirubin can inhibit this64. It can also inhibit the
chemotactic activity of granulocytes62. Bilirubin can
inhibit phytohaemoagglutinin stimulated prolifera-
162 tion of lymphocytes In vitro. It can decrease the
numbers ofantibody forming cells
163 and inhibit anti-
body-dependent cellular cytoxicity84. There seems to
be a relationship between serum bilirubin levels and
cellular immune responses in jaundiced patients85.
Stimulatory Effects
Bilirubin can stimulate macrophages and granulocytes in
vitro to phagocytose16. It can also increase Fc receptors
on peritoneal macrophages166. The proportion of acti-
vated lymphocytes is increased after bilirubin infusion161.
Other Factors
Hanai
68 reported that thromboxane may be another
mediator of importance in obstructive jaundice.
Thromboxanes are also immune stimulators and
monocyte/macrophages are major producer of these
eicosanoids.
SUMMARY OF IMMUNE FUNCTION IN
JAUNDICE
Although significant achievements have been made,
there remain a great many un-answered questions,
controversies, and in some cases confusion. In the
past immune suppression, depression, or inhibition
were terms simply used to describe the immune func-
tional state in these patients. This is clearly no longer
appropriate as the situation is far more complex. In
the last few years, the identification of a variety of
immune regulators and other insights into immune
systems (surface molecules and so on) has revealed
that there exists an infinitely more complex immune
regulation network, and therefore a single immune
parameter, phagocytosis for example, is inadequate
to describe or to reflect immune function. Many
earlier papers describing RES depression have used
an in vivo clearance of particles or pathogens. There is
increasing criticism of this method of measuring im-
mune function, as clearance of different particles may
vary and reflect the complex biological response of the
host including circulatory factors rather than just RES
or immune functions6.
The current literature suggests that in general,
monocyte/macrophage secretory functions (cytokines,
lysosomal enzymes, superoxide and prostaglandins) are
up-regulated, while its phagocytic functions are either
depressed or unchanged. Assays of cellular immunity
may reveal depression. Neutrophil superoxide produc-
tion is increased but changes in phagocytic function are
not yet clear. A proposed mechanism may be that when
biliary obstruction first appears, there is a transient or
sustained endotoxaemia thatmay activate cytokine pro-
duction from monocyte/macrophages and other im-
mune cells. Endotoxin togetherwith cytokines and other
mediators may prime or activate immune functions and
the inappropriately activated mechanisms may cause
damage to the host. This mechanism is similar to that
seen in sepsis and major trauma. The other biochemical
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salts may induce other modifications of the immune
system. The authors therefore recommend the term
"immune malfunction" or "immune dysfunction" rather
than immune suppression in these circumstances.
MEANS TO RESTORE THE IMMUNE
FUNCTION IN JAUNDICE
Biliary Drainage
This may prove to be the best way to intervene,
relieving both jaundice and restoring immune func-
tions. Katz has shown that 2 weeks after choledo-
choduodenostomy in jaundiced animals, the impaired
trapping of bacteria in the liver was restored and the
increased trapping of bacteria in the lung was
also reversed3:. Surgical drainage (choledochoduo-
denostomy) may restore the decreased IGF-I levels in
jaundiced animal145. Ding et al.
39 also showed that in
jaundiced rats, week after choledochoduodenostomy,
the RES uptake ofinfused bacteria retumed to normal.
A certain interval of time is needed for the RES to
recover. Thompson
17 also showed that depressed
lymphocyte functions can be reversed either by internal
or external drainage, but particularly internal drainage.
Percutaneous transhepatic biliary drainage will reduce
the secretoryIgA levels and therefore improve the bile to
serum ratio of IgA116. Internal biliary drainage may
36 reverse the depressed lymphocyte functions 37, 111.
There has been debate as to whether it is simply
drainage of bile that is important or returning bile
flow to the bowel1’148’49.
Although biliary drainage seems best for restoring
immune functions it takes time to show its effects, and
it is important that intervention aimed directly at the
immune system should also be considered, ifpossible.
CHEMOINTERVENTION
Lactulose and Bile Salt
Pinocytosis of colloidal carbon and phagocytosis of
sheep red cells by Kupffer cells can be inhibited by
cholic acid (CA) and chenodeoxycholic acid (CDCA)
156. CA or CDCA plus endotoxin also inhibits the
endocytic function. This suggests that bile salts as well
as endotoxin influences Kupffer cell functions.
155 Lactulose and bile salts (particularly deoxycholic
acid)
169 may inhibit endotoxin induced TNF produc-
tion by normal or jaundiced monocytes. CDCA and
taurochenodeoxycholic acid also inhibit monocyte
IL-1 and IL-6 production, whereas ursodeoxycholic acid
and tauroursodeoxycholic acid are less effective19’58.
This suggests that selective use of bile salts may be
beneficial. The same group has also shown that both
CDCA andUDCA particularly the former, have strong
inhibitory effects on lymphocyte proliferation in the
jaundiced animal. Indeed, lactulose and sodium de-
oxycholate have also been reportedby Pain
170 toprevent
the postoperative renal dysfunction in patients with
obstructive jaundice.
Mannitol71 has been shown to be beneficial in pa-
tients with obstructivejaundice. The exact role ofCCK
(cholecystokinin) in jaundice is not clear (although it is
implicated thatCCKmay be related to the enlargement
of eosinophilic granules)172. CCK however is greatly
increased in jaundiced animal (rats) and CCK receptor
antagonist have a beneficial effect in these jaundiced
animals173.
Anti-Endotoxin Treatment
Early studies using Polymixin B to reduce endotoxin in
the blood has proved to be inefficient in patients74.
Shibayama
75 showed that anti-endotoxin agents, poly-
mixin B, neomycin and lactulose failed to prevent
endotoxin induceddamage to the liverand biliary system.
Recently, Houldijk
176 reported that cholestyramine, an
endotoxinbindermaybeused inpreventingendotoxamia
related renal damage in jaundice. In their animal studies
(rats), they showed that by using cholestyramine, the
reduced renal blood flow injaundicemay be significantly
reversed. This may also prevent the further reduction of
renal blood flow injaundiced rats after surgery77.
The use of anti-endotoxin antibody clinically may
provide another approach. However, clinical trials us-
ing an antibody in patients with sepsis and other dis-
eases has proved not to be of benefit to the patients.
RES Suppressants and Stimulants
The precise status of the RES is not clear in jaundice
and therefore both RES supressants and stimulants
have been studied in these subjects.
Ding et al.
78 reported that by using a liposome
encapsulated synthetic macrophage stimulus, muramyl
dipeptide, it was possible to modify the impaired RES
clearance ofinfused bacteria injaundiced rats and also
modify the depressed RES phagocytic index78 by pre-
179 venting bacterial translocation Pain
45 showed that a
muramyl dipeptide analogue may improve the pro-
longed clearance ofmicro-aggregated human albumin
in jaundice both in human and in rats.136 W.G. JIANG AND M.C.A. PUNTIS
Manipulating RES function with various depres-
sants or stimulants has also been reported by A1-
Tuwaijri18. The RES suppressant, methyl palmitate,
modified liver damage by various agents, on the other
hand the RES stimulant Glucan worsened the liver
damage. Shibayama
TM has also shown that the RES
suppressants, cortisone acetate, methyl palmitate and
gadolinium chloride may also improve mortality and
prevent endotoxin induced hepatotoxicity.
An extract ofTinospora Cordifolia has been shown
to reverse the impaired neutrophil phagocytosis in
jaundice (human and rat)67. Muramyl dipeptide also
improves the impaired phagocytosis of mononuclear
phagocytes182.
Phagocytosis consists of a series of events, from
opsonization, antigen recognition, antigen binding
to cell surface, ingestion, acidification, fusion with
lysosomes and subsequent killing and digestion. Al-
though much research has shown the phagocytic
defect in the RES, there is, however, no information
about which part of the process is damaged and
therefore the non-specific stimuli used so far may
not have much beneficial effect. Indeed the reported
work so far has failed to examine other immune
functions after giving an immune stimulant. Such
non-specific stimulants may, apart from enhancing
the phagocytic process, also stimulate other un-
wanted effects such as toxic extracellular superoxide
and lysosomal enzyme secretions leading to further
damage to the tissues.
Other Agents
FumaruloTM and Conese
85 showed that retinoids, anti-
inflammatory agents, may inhibit the respiratory burst
and degranulation in stimulated neutrophils and can
also inhibit the procoagulant activity of mononuclear
phagocytes, which has been shown to be increased in
jaundice46’83’86’87’88. The clinical application of this for
patients, however, needs to be further investigated.
Uchino showed that prophylactic infusion of acti-
vated proteinC (APC) injaundiced animalsmay signi-
ficantly modify the hemorrhagic disorder that may be
related to mononuclear and endothelial cell suscepti-
bility to endotoxin186’187.
Arginine, a T cells stimulator may modify the dys-
functioning lymphocytes in the immune system in
jaundice as shown by LiTM. Arginine has also been
shown to modify delayed type hyper-sensitivity in
jaundiced animals183.
Cytokine Antibody and Antagonist
The devastating effects ofsome cytokines (TNF, IL-
l, IL-6 for example) have been shown in various
diseases, sepsis, trauma, burns, inflammatory bowel
diseases and rheumatoid arthritis. There are various
studies using cytokine antibodies or antagonists to
reduce these cytokine induced effects. Because the
levels of various cytokines are raised in jaundiced
patients and animals, anti-cytokine antibodies or
cytokine antagonists may be a means to reduce cyto-
kine mediated side effects.
Zhou
143 used PAF receptor antagonist in jaundiced
animals and this reduced free radical levels andmodified
the liver damage seen in this model.
Essential Fatty Acid
EFA’s, as an immune regulator, have been used in a
variety of clinical situations. Recent work151’88 showed
that one of the n-6 essential fatty acids, gamma lino-
lenic acid and its lithium salt, have strong regula-
tory effects on both monocytes and neutrophils.
The effects are dependent on the cell’s functional
status. EFA’s inhibitTNF and hexosaminidase produc-
tion from activatedjaundiced monocytes, but stimulate
TNF production from normal monocytes. Rheuma-
toid arthritis patients have a similar immune back-
ground to jaundiced patients, with activated monocyte/
macrophages (proteolytic enzymes and cytokine pro-
duction), neutrophils (reactive oxygen metabolite pro-
duction), and lymphocytes (cytokine production). In
recent years, both n-3 and n-6 fatty acids have been
used in these patients and overall clinical and im-
munological responses are satisfactory. This ap-
proach may also be useful in jaundiced patients
from the preliminary in vitro results.
CONCLUSIONS
Patients with obstructivejaundice, have increased peri-
operative complications and significant immunologi-
cal dysfunction or malfunction. While the phagocytic
functions of the RES have been shown to be sup-
pressed, other immune functions such as monocyte
secretions, neutrophil superoxide productions, circu-
lating cytokines are largely up-regulated. More work
must be done to investigate further the details of these
changes. Strategies should also be designed to restore
normal immune functionwhen this is appropriate or to
allow the immune function to be optimised to deal with
pathological situations such as sepsis.IMMUNE FUNCTIONS IN OBSTRUCTIVE JAUNDICE 137
ABBREVIATIONS
CCK Cholecystokinin
CDCA Chenodeoxycholic acid
GM-CSF Granulocyte macrophage colony
stimulating factor
IGF
M-CSF
PHA
RES
TNF
CA
EGF
IFN
LPS
PAF
PMA
TGF
TNFR
Insulin-like growth factor
Macrophage colony stimulating factor
Phytoheamagglutinin
Reticulo endothelial system
Tumour necrosis factor
Cholic acid
Epidermal growth factor
Interferon
Lipopolysaccharide
Platelet activating factor
Phorbol myristate acetate
Transforming growth factor
Tumour necrosis factor receptor
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The Internal Biliary Fistula- Reappraisal
of Incidence, Type, Diagnosis and
Management of 33 Consecutive Cases
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To reevaluate the current features of spontaneous internal biliary fistulas, we reviewed 1,929 consecutive
patients who had been treated for biliary tract diseases during the recent 12-year period. Thirty-three
patients had internal biliaryfistulas and the incidence was 1.9%. Of33 patients, 20 werewomen and 13 were
men with the average age 63 years, and theirmean duration ofillness was 4 years. A total of37 fistulas were
found and the mostcommon type was choledochoduodenal (62%), followed by cholecystoduodenal (19%),
cholecystocholedochal (11%) and cholecystocolonic (8%) fistulas. Internal biliary fistulas of thirty-one
patients were caused by biliary stones and those of two patients by malignant tumors. All of the 17 bile
samples examined were bacteria positive and the majority of calculi were brown pigment stones. All of the
choledochoduodenal fistulas were correctly diagnosed by endoscopic retrograde cholangiography. In 14
patients with cholecystoenteric or cholecystocholedochal fistulas, direct evidence of the internal fistula was
obtained only in 7 patients(50%) preoperatively. Pneumobilia, a small atrophic gallbladder adherent to the
neighboring organs and a history of spontaneous disappearance of jaundice in elderly patients may
indicate the presence ofa cholecystoentric fistula. Since the preoperative diagnostic rate for internal biliary
fistula involving the gallbladder is still low, care is necessary before and at the time of surgery especially
during laparoscopic cholecystectomy for elderly patients with cholelithiasis.
KEY WORDS: Internal biliary fistula cholelithiasisendoscopicretrogradecholangiography
laparoscopic cholecystectomy
INTRODUCTION
Although traditional open cholecystectomy and re-
cently developed laparoscopic cholecystectomy show
very low mortality and morbidity rates 1’ 2, the presence
of spontaneous internal biliary fistulae is reported to
increase the morbidity rate considerably and its poten-
tial lethality has been appreciated3-5. The reported inci-
dence of internal biliary fistulas is about 2% of total
biliary diseases and the most common type has been
reported to be a cholecystoduodenal fistula, followed
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by cholecystocolonic and cholecystogastric fistulas3’4.
Their clinical importance as well as the management
depends on the etiology and type of the fistulas. The
treatment option can be selected only when such infor-
mation is available. Although it is sometimes difficult to
diagnose correctly the type of internal biliary fistula
preoperatively, surgeons must be aware of the possible
presence of an internal biliary fistula before surgical
intervention. This might be particularly truewhen con-
sidering laparoscopic cholecystectomy.
The recent advances in hepatobiliary imaging tech-
niques have allowed us to reevaluate hepatobiliary
diseases. With the aid of endoscopic retrograde
cholangiography, choledochoduodenal fistulas in the
periampullary region have been found more frequently
than ever7-9. Despite the improvement in imaging
modalities, little literature is currently available about
143